<li>eluxadoline<p>diphenhydramine, eluxadoline.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions.</p></li><li>isocarboxazid<p>isocarboxazid increases effects of diphenhydramine by Other (see comment). Avoid or Use Alternate Drug. 
Comment: Isocarboxazid should not be administered in combination with antihistamines because of potential additive CNS depressant effects.  MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .</p></li><li>mefloquine<p>mefloquine increases toxicity of diphenhydramine by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.</p></li><li>pramlintide<p>pramlintide, diphenhydramine.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.</p></li><li>quinidine<p>quinidine, diphenhydramine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of prolonged QTc interval.</p></li><li>sodium oxybate<p>diphenhydramine, sodium oxybate.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Additive CNS depression.</p></li><li>thioridazine<p>diphenhydramine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.</p></li><li>tranylcypromine<p>tranylcypromine increases effects of diphenhydramine by Other (see comment). Avoid or Use Alternate Drug. 
Comment: Tranylcypromine should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .</p></li>